4528 - 7 months RECTANGLE══════════════════════════════
Since 2014, my markets approach is to spot
trading opportunities based solely on the
development of
CLASSICAL CHART PATTERNS
🤝Let’s learn and grow together 🤝
══════════════════════════════
Hello Traders ✌
After a careful consideration I came to the conclusion that:
- it is crucial to be quick in alerting you with all the opportunities I spot and often I don't post a good pattern because I don't have the opportunity to write down a proper didactical comment;
- since my parameters to identify a Classical Pattern and its scenario are very well defined, many of my comments were and would be redundant;
- the information that I think is important is very simple and can easily be understood just by looking at charts;
For these reasons and hoping to give you a better help, I decided to write comments only when something very specific or interesting shows up, otherwise all the information is shown on the chart.
Thank you all for your support
🔎🔎🔎 ALWAYS REMEMBER
"A pattern IS NOT a Pattern until the breakout is completed. Before that moment it is just a bunch of colorful candlesticks on a chart of your watchlist"
═════════════════════════════
⚠ DISCLAIMER ⚠
The content is The Art Of Charting's personal opinion and it is posted purely for educational purpose and therefore it must not be taken as a direct or indirect investing recommendations or advices. Any action taken upon these information is at your own risk.
A2N6NC trade ideas
ONO PHARMA partners with Bristol Myers SquibbBristol-Myers Squibb ( BMY ), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients with micro-satellite stable metastatic colorectal cancer, the most common form of mCRC. Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in a Phase III study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Around 95% of mCRC patients have MSS tumors, for which I-O monotherapy treatment approaches have shown limited activity. In a Phase 1b trial from Japan, the combination of regorafenib and nivolumab has shown 'promising' preliminary efficacy results. Further terms of the clinical collaboration were not disclosed.
Read more at:
thefly.com
ONO PHARMA partners with Bristol Myers SquibbTODAY'S ANNOUNCEMENT
Bristol-Myers Squibb (BMY), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients with micro-satellite stable metastatic colorectal cancer, the most common form of mCRC. Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in a Phase III study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Around 95% of mCRC patients have MSS tumors, for which I-O monotherapy treatment approaches have shown limited activity. In a Phase 1b trial from Japan, the combination of regorafenib and nivolumab has shown 'promising' preliminary efficacy results. Further terms of the clinical collaboration were not disclosed.
Read more at:
thefly.com
AVERAGE ANALYSTS PRICE TARGET $7.26
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 22
COMPANY PROFILE
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.